Tumour budding and its clinical implications in gastrointestinal cancers

被引:0
|
作者
Inti Zlobec
Martin D. Berger
Alessandro Lugli
机构
[1] University of Bern,Institute of Pathology
[2] University Hospital Bern,Department of Medical Oncology, Inselspital
[3] University of Bern,undefined
来源
British Journal of Cancer | 2020年 / 123卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tumour budding in colorectal cancer has become an important prognostic factor. Represented by single cells or small tumour cell clusters at the invasion front of the tumour mass, these tumour buds seem to reflect cells in a ‘hybrid’ state of epithelial–mesenchymal transition, and evidence indicates that the presence of these entities is associated with lymph node metastasis, local recurrence and distant metastatic disease. The International Tumour Budding Consensus Conference (ITBCC) has highlighted a scoring system for the reporting of tumour budding in colorectal cancer, as well as different clinical scenarios that could affect patient management. Other organs are not spared: tumour budding has been described in numerous gastrointestinal and non-gastrointestinal cancers. Here, we give an update on ITBCC validation studies in the context of colorectal cancer and the clinical implications of tumour budding throughout the upper gastrointestinal and pancreatico-biliary tract.
引用
收藏
页码:700 / 708
页数:8
相关论文
共 50 条
  • [1] Tumour budding and its clinical implications in gastrointestinal cancers
    Zlobec, Inti
    Berger, Martin D.
    Lugli, Alessandro
    BRITISH JOURNAL OF CANCER, 2020, 123 (05) : 700 - 708
  • [2] Tumour budding in solid cancers
    Lugli, Alessandro
    Zlobec, Inti
    Berger, Martin D.
    Kirsch, Richard
    Nagtegaal, Iris D.
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (02) : 101 - 115
  • [3] Tumour budding in solid cancers
    Alessandro Lugli
    Inti Zlobec
    Martin D. Berger
    Richard Kirsch
    Iris D. Nagtegaal
    Nature Reviews Clinical Oncology, 2021, 18 : 101 - 115
  • [4] Prognostic value of tumour budding in stomach cancers
    Kucuk, Sirin
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2021, 75 (12)
  • [5] Molecular tumour board in gastrointestinal cancers
    Bielo, L. Boscolo
    Crimini, E.
    Repetto, M.
    Barberis, M.
    Battaiotto, E.
    Katrini, J.
    Martino, E.
    Gaudio, G.
    Lombardi, M.
    Zanzottera, C.
    Aurilio, G.
    Belli, C.
    Zhan, Y.
    Fuorivia, V.
    Marsicano, R. M.
    Etessami, J. D.
    Zagami, P.
    Marra, A.
    Trapani, D.
    Salimbeni, B. Taurelli
    Criscitiello, C.
    Ciardiello, D.
    Lavinia, B.
    Gervaso, L.
    Cella, C. A.
    Spada, F.
    Zampino, M. G.
    Fusco, N.
    Fazio, N.
    Rocco, E. Guerini
    Curigliano, G.
    ESMO OPEN, 2025, 10 (04)
  • [6] The Crosstalk and Clinical Implications of CircRNAs and Glucose Metabolism in Gastrointestinal Cancers
    Luo, Xiaonuan
    Peng, Yin
    Fan, Xinmin
    Xie, Xiaoxun
    Jin, Zhe
    Zhang, Xiaojing
    CANCERS, 2023, 15 (08)
  • [7] MET signalling pathway and its therapeutic implications in gastrointestinal cancers
    Zaanan, Aziz
    Laurent-Puig, Pierre
    Taieb, Julien
    BULLETIN DU CANCER, 2014, 101 (01) : 25 - 30
  • [8] Understanding Cancer Cachexia and Its Implications in Upper Gastrointestinal Cancers
    Brown, Leo R.
    Laird, Barry J. A.
    Wigmore, Stephen J.
    Skipworth, Richard J. E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2022, 23 (12) : 1732 - 1747
  • [9] Understanding Cancer Cachexia and Its Implications in Upper Gastrointestinal Cancers
    Leo R. Brown
    Barry J. A. Laird
    Stephen J. Wigmore
    Richard J. E. Skipworth
    Current Treatment Options in Oncology, 2022, 23 : 1732 - 1747
  • [10] Tumour markers in gastrointestinal cancers - EGTM recommendations
    不详
    ANTICANCER RESEARCH, 1999, 19 (4A) : 2811 - 2815